Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the US Food and Drug Administration (FDA) for adults with relapsed or refractory ...

Pirtobrutinib significantly improved progression-free survival in treatment-naive CLL/SLL patients, reducing disease progression risk by 80% compared to bendamustine plus rituximab. The trial ...

A common fear among drivers is accidentally shifting to reverse while on the move, which many assume could be catastrophic for the vehicle. But can you really hurt your gearbox if you — or some nosey ...

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, recently sold a significant chunk of his company's common stock. The CEO of Recursion Pharmaceuticals recently disposed of 120 ...

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

For many older homeowners, home equity has become one of the most valuable financial resources they have. Case in point? U.S. homeowners held a collective $17.8 trillion in home equity as of mid-2025, ...